Idiopathic generalized epilepsy
MONDO:0005579A generalised epilepsy that encompasses several common seizure phenotypes including childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy and epilepsy with generalized tonic-clonic seizures alone. These epilepsy syndromes have polygenic inheritance with or without environmental factors contributing to seizure susceptibility. Seizure types include one or a combination of absence seizures, myoclonic seizures and/or generalized tonic-clonic seizures.
Also known as: generalized epilepsy, EIG, IGE, epilepsy, idiopathic generalized, hereditary idiopathic generalized epilepsy, idiopathic generalised epilepsy, idiopathic generalized epilepsy
36 clinical trials for this condition and its sub-types, 11 tagged with Idiopathic generalized epilepsy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Idiopathic generalized epilepsy
-
Variable-age onset idiopathic generalized epilepsy syndrome 0 trials · 17 incl. sub-types
4 sub-types
- Epilepsy with generalized tonic-clonic seizures 11 trials
- Juvenile absence epilepsy 3 trials
- Juvenile myoclonic epilepsy 3 trials Sub-types →
- Epilepsy, idiopathic generalized 20 0 trials
-
Childhood-onset idiopathic generalized epilepsy syndrome 0 trials · 7 incl. sub-types
1 sub-type
- Childhood absence epilepsy 7 trials Sub-types →
Most studied deeper sub-types
-
New epilepsy drug candidate aims to tame severe seizures
Disease control CompletedThis study tests whether cenobamate, an experimental anti-epileptic drug, can safely reduce primary generalized tonic-clonic (PGTC) seizures when added to a person's usual seizure medications. Adults and adolescents aged 12 and older with PGTC seizures are randomly assigned to re…
Phase 3 • Sponsor: SK Life Science, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New epilepsy drug shows promise for Long-Term seizure control
Disease control CompletedThis study looked at the long-term safety of the drug cenobamate when added to existing treatment for people with primary generalized tonic-clonic seizures. A total of 147 participants who completed an earlier study took cenobamate for up to 52 weeks. Researchers tracked side eff…
Phase 3 • Sponsor: SK Life Science, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Brain device zaps seizures in Tough-to-Treat epilepsy
Disease control CompletedThis study tested a brain implant (RNS System) that delivers targeted electrical stimulation to the thalamus to reduce seizures in people aged 12 and older with drug-resistant idiopathic generalized epilepsy. The goal was to see if the device is safe and effective at cutting down…
Sponsor: NeuroPace • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Walking your way to a better memory with epilepsy?
Symptom relief CompletedThis study tested whether a 6-week exercise program could improve memory in 71 adults with idiopathic generalized epilepsy. Participants either exercised or did nothing extra, and researchers measured memory and brain changes. The goal was to see if exercise helps memory and if t…
Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Epilepsy study aims to predict who will respond to treatment
Knowledge-focused CompletedThis completed study followed 316 people with idiopathic generalized epilepsy, including those newly diagnosed and those already known to respond or not respond to treatment. Researchers collected data from seizure diaries, fitness trackers, quality-of-life surveys, and cognitive…
Sponsor: NYU Langone Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Scientists probe Dopamine's role in epilepsy with yawn and blink test
Knowledge-focused CompletedThis study looked at how the brain chemical dopamine behaves in people with idiopathic generalized epilepsy compared to healthy volunteers. Researchers measured yawning and blinking after giving a low dose of apomorphine, a drug that mimics dopamine. The goal was to understand br…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC